Adaptive Biotechnologies Corporation $ADPT Shares Sold by Aristotle Atlantic Partners LLC

Aristotle Atlantic Partners LLC lowered its position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 7.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,714,346 shares of the company’s stock after selling 128,098 shares during the quarter. Aristotle Atlantic Partners LLC’s holdings in Adaptive Biotechnologies were worth $23,795,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ADPT. Caitong International Asset Management Co. Ltd acquired a new stake in Adaptive Biotechnologies in the fourth quarter valued at $28,000. EverSource Wealth Advisors LLC boosted its position in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares in the last quarter. KBC Group NV acquired a new position in shares of Adaptive Biotechnologies during the 1st quarter worth about $45,000. Assetmark Inc. increased its holdings in shares of Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at about $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Ratings Changes

ADPT has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Guggenheim increased their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. BTIG Research restated a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, June 17th. Finally, Morgan Stanley upped their target price on shares of Adaptive Biotechnologies from $18.00 to $20.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.83.

Adaptive Biotechnologies Stock Performance

ADPT stock opened at $22.27 on Friday. The stock has a market capitalization of $3.56 billion, a PE ratio of -67.48 and a beta of 2.07. The company has a fifty day moving average of $18.49 and a 200-day moving average of $16.42. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $23.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.20) earnings per share. Equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Harlan S. Robins sold 386,240 shares of Adaptive Biotechnologies stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.01, for a total value of $8,501,142.40. Following the sale, the insider directly owned 1,019,658 shares in the company, valued at $22,442,672.58. The trade was a 27.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52. Following the completion of the sale, the insider directly owned 221,278 shares of the company’s stock, valued at approximately $4,677,816.92. This trade represents a 41.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 832,424 shares of company stock valued at $17,320,824 over the last 90 days. 5.70% of the stock is owned by corporate insiders.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.